The BTX 1503 Phase 2 clinical trial has been designedto deliver data that allows Botanix to explore potential licensing and other corporate opportunities uponsuccessful completion of the study around mid-2019. Plenty of time here.....
Ann: Annual Report to shareholders, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 35.0¢ | $230.9K | 653.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 89180 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 138744 | 8 |
View Market Depth
| Last trade - 10.50am 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
